Stockreport

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference [Yahoo! Finance]

Coya Therapeutics, Inc.  (COYA) 
PDF 4-HNE levels may serve as a potential surrogate biomarker to track efficacy of ALS disease modifying treatments, such as COYA 302 HOUSTON, March 12, 2024 BUSINESS WIR [Read more]